February 26, 2020 / 10:35 PM / a month ago

BRIEF-Eloxx Strengthens Its Commitment To Cystic Fibrosis Through Reallocating Resources

Feb 26 (Reuters) - Eloxx Pharmaceuticals Inc:

* ELOXX STRENGTHENS ITS COMMITMENT TO CYSTIC FIBROSIS THROUGH REALLOCATING RESOURCES

* ELOXX PHARMACEUTICALS INC - REITERATE TOPLINE DATA FROM PHASE 2 CYSTIC FIBROSIS CLINICAL TRIALS FOR ELX-02 EXPECTED IN H1 2020

* ELOXX PHARMACEUTICALS INC - GREGORY WILLIAMS APPOINTED CHIEF EXECUTIVE OFFICER AND NEIL BELLOFF CHIEF OPERATING OFFICER

* ELOXX PHARMACEUTICALS INC - HEADCOUNT REALIGNMENT TO REDUCE OPERATING EXPENSES AND SIGNIFICANTLY EXTEND FUNDING OF OPERATIONS THROUGH END OF 2021

* ELOXX PHARMACEUTICALS - EXPECTS TO REPORT TOPLINE DATA FROM ITS PHASE 2 CYSTIC FIBROSIS CLINICAL TRIAL PROGRAM FOR ELX-02 DURING FIRST HALF OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below